These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29250533)

  • 1. PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells.
    Zheng F; Dang J; Zha H; Zhang B; Lin M; Cheng F
    Biomed Res Int; 2017; 2017():1293201. PubMed ID: 29250533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
    Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
    Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Clark CA; Gupta HB; Sareddy G; Pandeswara S; Lao S; Yuan B; Drerup JM; Padron A; Conejo-Garcia J; Murthy K; Liu Y; Turk MJ; Thedieck K; Hurez V; Li R; Vadlamudi R; Curiel TJ
    Cancer Res; 2016 Dec; 76(23):6964-6974. PubMed ID: 27671674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.
    Kleffel S; Posch C; Barthel SR; Mueller H; Schlapbach C; Guenova E; Elco CP; Lee N; Juneja VR; Zhan Q; Lian CG; Thomi R; Hoetzenecker W; Cozzio A; Dummer R; Mihm MC; Flaherty KT; Frank MH; Murphy GF; Sharpe AH; Kupper TS; Schatton T
    Cell; 2015 Sep; 162(6):1242-56. PubMed ID: 26359984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
    Nedrow JR; Josefsson A; Park S; Ranka S; Roy S; Sgouros G
    J Nucl Med; 2017 Oct; 58(10):1560-1566. PubMed ID: 28522738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.
    Zhu B; Tang L; Chen S; Yin C; Peng S; Li X; Liu T; Liu W; Han C; Stawski L; Xu ZX; Zhou G; Chen X; Gao X; Goding CR; Xu N; Cui R; Cao P
    Oncogene; 2018 Sep; 37(36):4941-4954. PubMed ID: 29786078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
    Li T; Zhang C; Zhao G; Zhang X; Hao M; Hassan S; Zhang M; Zheng H; Yang D; Liu L; Mehraein-Ghomi F; Bai X; Chen K; Zhang W; Yang J
    Cancer Lett; 2020 May; 477():19-30. PubMed ID: 32120023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B.
    Lu S; Sun Z; Hu W; Yin S; Zhao C; Hu H
    Cancer Sci; 2021 May; 112(5):1878-1887. PubMed ID: 33583114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
    Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
    Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential.
    Clark CA; Gupta HB; Curiel TJ
    Autophagy; 2017 May; 13(5):987-988. PubMed ID: 28368722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells.
    Santini R; Vinci MC; Pandolfi S; Penachioni JY; Montagnani V; Olivito B; Gattai R; Pimpinelli N; Gerlini G; Borgognoni L; Stecca B
    Stem Cells; 2012 Sep; 30(9):1808-18. PubMed ID: 22730244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
    Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
    Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of T-cell activation by malignant melanoma initiating cells.
    Schatton T; Schütte U; Frank NY; Zhan Q; Hoerning A; Robles SC; Zhou J; Hodi FS; Spagnoli GC; Murphy GF; Frank MH
    Cancer Res; 2010 Jan; 70(2):697-708. PubMed ID: 20068175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
    Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
    Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.
    Contreras-Sandoval AM; Merino M; Vasquez M; Trocóniz IF; Berraondo P; Garrido MJ
    Oncotarget; 2016 Nov; 7(47):76891-76901. PubMed ID: 27764774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.